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ABSTRACT   
Background 
There is good evidence for the benefits of short-term Cognitive Stimulation 
Therapy for dementia but little is known about possible long-term effects. 
Aims  
To evaluate the effectiveness of maintenance Cognitive Stimulation Therapy 
for people with dementia in a single-blind, pragmatic randomised controlled 
trial including a sub-study with participants taking acetylcholinesterase 
inhibitors (ACHEIs).  
Method  
The participants were 236 people with dementia from nine care homes and 
nine community services.  Prior to randomisation all participants received the 
seven-week 14-session CST programme. The intervention group received the 
weekly Maintenance CST group programme for 24 weeks. The control group 
received usual care. Primary outcomes were cognition and quality of life.  
Results  
For the intervention group at the six-month primary end point there were  
significant benefits for self-rated quality of life (QoL-AD p=0.03). At three 
months there were improvements for proxy-rated quality of life (QoL-AD 
p=0.01: DEMQOL p=0.03), and activities of daily living (p=0.04). The 
intervention sub-group taking ACHEIs showed cognitive benefits (on the 
MMSE) at three (p=0.03) and six months(p=0.03) .  
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Conclusions Continuing CST improves quality of life; and improves cognition 
for those taking ACHEIs.   
 
WORD COUNT: main text 3571 
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INTRODUCTION 
 
There is good evidence for the benefits of cognitive stimulation for people 
with dementia.1 A recent Cochrane review showed that cognitive stimulation 
improved both cognition and quality of life.2 The review concluded the 
benefits of cognitive stimulation enhanced those of medication, and that it 
was effective whether or not acetylcholinesterase inhibitors (ACHEIs) were 
prescribed.2 The 2011 World Alzheimer report concluded “there is strong 
evidence to support cognitive stimulation programmes and these 
interventions should therefore be routinely offered".3 Cognitive stimulation is 
a psychological intervention for dementia that targets cognitive and social 
functioning and is designed to enhance general cognitive abilities. Cognitive 
Stimulation Therapy (CST) is a well-defined evidence-based version of 
cognitive stimulation which is standardised, including 2 training manuals and 
a DVD.4 CST was developed following review of a related approach known 
as Reality Orientation (RO)5 and evaluated CST in a pilot trial,6 followed by a 
full trial,4 and developed a manual7 and a training DVD. CST is now used 
widely across the UK and in several other countries. A pilot study of 
maintenance CST which continued for an extra 16 weekly sessions beyond 
the standard seven-week (14-session) CST programme8 found a significant 
improvement in cognitive function compared with CST alone. The Cochrane 
Review found no link between duration or frequency of the programme and 
degree of improvement.2 Some studies have continued cognitive stimulation 
for six months or more,9,10 but there is little evidence about how far potential 
benefits may continue after sessions end. The Cochrane Review suggested 
that after the sessions finished the effects on cognition were evident for at 
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most three months;2 and another study found no continuing effects at ten 
months.11 This trial aimed to evaluate the effectiveness of Maintenance CST 
in improving cognition and quality of life in people with dementia who have 
completed the standard CST programme. Hence the intervention group 
would continue with maintenance CST whereas the control group would have 
standard CST only followed by treatment as usual.12  In addition, a sub-study 
focused on the effects of maintenance CST on people with dementia taking 
ACHEIs. 
 
METHODS 
Study Design 
This was a single-blind, multi-centre, pragmatic randomised controlled trial 
comparing (1) Maintenance CST groups after completing standard CST vs (2) 
standard CST only followed by treatment as usual.13 There was no 
modification in design or eligibility criteria from the study protocol12 available at 
http://www.trialsjournal.com/content/pdf/1745-6215-11-46.pdf. The clinical trial 
registration number is ISRCTN26286067.  
 
Participants  
Potential centres were screened for eligibility to determine whether there were 
sufficient numbers of potential participants with dementia, using the inclusion 
criteria flow chart. Participants all met the DSM-IV criteria for dementia14 
using the diagnostic algorithm and most had either Alzheimers or vascular 
dementia.  All had mild (45%) to moderate dementia (55%) on the Clinical 
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Dementia Rating scale;15 could communicate, hear and see well enough to 
participate in the group; had no major physical illness or disability, or 
diagnosed learning disability. All trial participants completed seven weeks of 
CST4 comprising fourteen twice-weekly 45-minute sessions according to the 
CST manual.7  
 
Approximately half of the participants from nine care homes, and half from 
nine community services within London, Essex and Bedfordshire.  The 
community centres included four  voluntary sector specialist dementia day 
centres, and five centres based in local Community Mental Health Teams for 
older people. The nine  care homes included; five provided by Social 
Services, one by the private sector, and three by a voluntary organisation.  Of 
21 centres approached, one refused and two had too few eligible participants. 
The study was approved by the Barking & Havering Local Research Ethics 
Committee in October 2008, ethical approval reference number: 08/H0702/68.  
 
Intervention  
After completion of the CST programme participants were randomised within 
each centre to either the (1) intervention group 24-week Maintenance CST 
(MCST) programme;16 or (2) the treatment as usual control group. Treatment 
as usual (TAU) varied across the 18 centres but other activities  were 
generally available to both groups. 
The Maintenance CST programme was based on the theory of cognitive 
stimulation as applied to the original CST programme.4 guided by the Medical 
Research Council framework for complex interventions.17,18 Each 
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Maintenance CST session has a specific theme or activity (e.g. current affairs; 
my life; word games) within a consistent structure including orientation-based 
activity, refreshments and a group song. Each group had two facilitators, one 
from the research team and one staff member from the participating centre 
(i.e. care home or community service). All facilitators had at least one year of 
experience in dementia care, and had attended the one-day CST training 
course.   
 
Outcome measures  
Participants were interviewed at baseline, before randomisation, at three 
months (intermediate end point) and after six months (primary end point). 
Researchers collected the proxy ratings of the quality of life measures, the 
NPI and the ADCS-ADL in structured interviews: with staff for participants in 
care homes; and with family carers for those in the community.  
 
 Primary outcomes 
 (1) Alzheimer’s Disease Assessment Scale – Cognition Subscale 
 (ADAS-Cog). This is the standard cognitive test used in clinical trials for 
 dementia.19 This comprises 11 tasks measuring memory, language, 
 praxis, attention and other cognitive abilities. Lower scores reflect better 
 cognition.  
 (1) Quality of Life in Alzheimer's Disease scale (Qol-AD)20. This is 
 recommended by the European consensus on outcome measures for 
 psychosocial interventions in dementia.21 The Qol-AD includes both self 
 rating and proxy rating (by family care or staff) versions and covers 13 
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 domains of quality of life. It has good internal consistency, validity 
 and reliability. Higher scores reflect better quality of life.  
 Secondary outcomes  
  (1) Mini-Mental State Examination (MMSE), a brief but widely used   
  generic test of cognitive function with higher scores indicating better   
  cognition.22 This is easier to complete than the  ADAS-Cog, but still has 
  good reliability and validity.  
   (2) Dementia Quality of Life scale (DemQoL).23 The DemQoL covers 
  five domains of quality of life and uses both self reporting and rating by 
  family carer or staff member as proxy with higher scores indicating  
  better quality of life. It has good internal consistency, inter-rater  
    reliability and concurrent validity and can generate a measure of utility. 
      (3) Neuropsychiatric Inventory (NPI).24 This assesses 10 behaviours 
 that commonly occur in dementia and has good validity and reliability. 
 Lower scores on this specific measure reflect better behaviour. 
 Total score is the sum of frequency x severity of each behaviour.  
 (4) Alzheimer's Disease Co-operative Study-Activities of Daily Living 
 (ADCS-ADL). This validated questionnaire assesses functional 
 capacity over the range of dementia severity.25 By summing 
 competencies this measure gives high scores to more able 
 respondents. 
 
Sample size  
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Based on the Cochrane Review we estimated effect size for Maintenance 
CST of 0.39 on the ADAS-Cog with power of 80% when using 5% significance 
level and estimating attrition at 15% between baseline and six months. This 
required a sample size of 230 participants randomised at baseline and an 
estimated 195 at follow up. With an estimated 60 participants with Alzheimer's 
disease and taking ACHEIs, this provided sufficient numbers for the 
maintenance CST/ACHEIs sub-study to estimate effect size and the feasibility 
of a full scale trial. 
 
Randomisation  
All participants completed the initial CST programme13 and were then 
allocated at random between (1) the intervention group receiving weekly 
Maintenance CST for 24 weeks or (2) the control group receiving treatment as 
usual (TAU). The NWORTH Clinical Trials Unit remotely randomised 
participants in equal proportions between groups after stratifying for: centre 
(community service or care home), whether ACHEI was prescribed, and 
previous CST group. The random allocation sequence was computer-
generated and in the ratio of 1:1. NWORTH emailed the individual allocation 
to the site researcher delivering the intervention and stored the allocation list 
under a secure password, which was not available to any study site staff. The 
scheduled treatment sessions, session records and participant records were 
saved at the site, strictly separated, and distant from the coordinating study 
centre. Once the trial was completed in each centre, records were transferred 
to the coordinating study centre and stored by the study centre administrator 
who was not involved in the assessment process or data analysis. This was in 
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order to avoid contamination. The nature of the intervention prevented us from 
blinding participants to their allocated group. However blind researchers 
conducted initial and subsequent interviews, generally in care homes or 
participants’ own homes. The statistician conducting the data analysis was 
also blind to group assignment. 
 
Statistical analysis 
We used the MACRO system to manage the data. Data was entered 
manually and audited internally for typing errors by hand, in order to ensure a 
low error rate. Data was transferred to SPSS and audited externally by 
NWORTH with hard copies of assessments. These audits entailed cross 
checking a random 10% sample of the electronic data with the paper records 
to ensure accurate entry. Both random and systematic data entry errors were 
identified and corrected. As the audits were carried out in parallel with data 
entry systematic errors could be corrected at an early stage. The dataset is 
available from the corresponding author at m.orrell@ucl.ac.uk. Participants’ 
consent was obtained, but the data presented are anonymised and risk of 
identification is low. For participants with some follow-up data, we imputed 
individual data missing within a scale according to the validated rules for that 
scale; and missing total scores by multiple regression on variables including 
allocated group, age, gender, ethnicity, marital status, whether prescribed an 
ACHEI, staff or family caregiver, centre type and individual centre (using 
random effects). We adopted a forward stepwise model, and used baseline 
scores to help predict scores at three months, then both of these to predict 
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scores at six months, since no participant missing at three months returned at 
six months.  
Primary analyses by treatment allocated used analysis of covariance to adjust 
all imputed data for baseline differences in age, gender, ethnicity, marital 
status, prescription of ACHEIs, proportion of family caregivers, individual 
centre (using random effects) and baseline score on the variable under 
analysis. We then estimated the effect of treatment from the resulting model. 
The maintenance CST/ ACHEIs trial platform followed the same methodology 
as for the primary analysis and used the interaction term between ACHEIs 
and the treatment group to identify any effect between the two factors for the 
outcome measures.  
 
Results 
The recruitment period took place between January 2009 and September 
2010. The final 24-week follow up was completed in May 2011. Of 272 people 
with dementia that started the CST groups and were considered for the trial, 
36 were withdrawn (Table 1). We followed up 218 participants (92% of 236; 
96% of those still alive) at 3 months and 199 (84% of 236; 89% of those still 
alive) at 6 months. The CONSORT flowchart (Figure 1) records the reasons 
for subsequent withdrawals. The withdrawal rate was similar in both arms of 
the trial. Of the 236 participants, 123 were allocated to the Maintenance CST 
group and 113 to usual care (TAU). The groups were well matched at 
baseline and randomisation avoided imbalances (Table 2). The mean age 
was 83 years and most participants were white females. On average 
 13 
participants allocated to the Maintenance CST groups attended 18 of the 24 
available sessions.    
Outcomes 
At the six-month primary end-point (Table 3),  the Maintenance CST group 
had  higher scores than the TAU group on self-rated QoL-AD (first primary 
outcome) which reached statistical significance with mean difference 1.78 
(95% CI 0.00 to 3.60; p=0.03). There were no significant differences on 
ADAS-Cog (second primary outcome). There were no significant differences 
in secondary outcomes at six months. There were two types of centre studied, 
care homes and community services. There were significant differences 
among the centres over and above that explained by centre type.  
 
At three months there were no significant differences on either primary 
outcome. For secondary outcomes, participants randomised to the 
intervention group had significantly better scores than controls on proxy 
ratings of quality of life (QoL-AD and DEMQOL) and daily activities. The mean 
difference on the proxy QoL-AD was 1.53 (95% CI 0.35 to 2.71; p=0.01); and 
for the proxy DEMQOL it was 3.24 (95% CI 0.24 to 6.24; p=0.03). The 
difference on the ADCS-ADL was 2.64 (95% CI 0.04 to 5.24; p=0.04).  
 
Quality of maintenance CST programme provision  
To estimate the quality of the maintenance CST provision after each session 
the researchers made ratings on a range of factors related to the successful 
running of the groups: manager’s attitude (0-2), centre atmosphere (0-2), co 
facilitators input (0-2), group atmosphere (0-2), and average number of 
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sessions attended by participants (0 = less than 12, 1 = 13–20, 2 = 21-24) with 
higher scores indicating better quality. Centres were divided into low quality 
(score 0-5) and high quality (score 6-10). Eight out of 9 community centres 
scored as high quality compared to only 6 out of 9 care homes. The quality 
indicator was incorporated into the model of analysis with primary outcome 
results, with baseline score, centre type, age and allocation as a fixed effect 
and within a random effect of centre nested within the interaction of quality 
and type. The analysis showed that both centre type and quality of CST 
provision were not significant in the model using either QoL-AD or ADAS-Cog. 
There were differences among the centres that could not be explained by 
amount of sessions attended or quality of CST provision. 
 
Maintenance CST/ ACHEI trial platform results 
There were no significant results in relation to primary outcomes. Table 4 
shows the observed means and SD at baseline. The means and SDs 
presented at follow-ups 1 and 2 are adjusted for the factors and covariates in 
the fitted model including the treatment group by ACHEIs interaction term. 
The follow-up means are standardised to a common baseline mean value. 
The significance levels quoted below are for the interaction term. Only for 
MMSE at both three and six months follow-up were significant interactions 
found. The results show that starting from a mean baseline MMSE of 17.8 
there was the smallest decrease to 17.25 (95% CI 14.63 to 19.87, p = 0.03) at 
follow-up 2 in those taking ACHEIs and receiving maintenance CST. The 
largest decrease occurred in those taking ACHEIs but with no maintenance 
CST where the mean was 14.62 (95% CI 11.81 to 17.43, p = 0.03). There 
 15 
were no other significant differences between groups in any other outcome 
measures. 
 
Between baseline and second follow up 92% had no changes to their to 
ACHEI status with three participants stopping (1 TAU/2 MCST) and 11 
starting (4 TAU/7MCST) medication.  
 
There were no differences between the groups (intervention and control) in 
the number of reported adverse events or severity. In the intervention group 
there were five deaths and four withdrawals due to health issues. In the usual 
care group there were six deaths and five withdrawals due to health issues. 
All events were judged as unrelated to trial treatment or assessment contacts 
by the study trial coordinator and Principal Investigator. 
 
DISCUSSION 
Main findings 
Cognitive stimulation for people with dementia is recognised as being 
effective2,13 and cost effective26, and CST in particular improves both 
cognition and quality of life.4,13  This trial finds that after the initial CST 
programme, a further 24-week course of weekly Maintenance CST improves 
quality of life at six-month follow up but confers no additional benefit to 
cognition. At six months it was only participants who reported improved quality 
of life (a small standardised difference of 0.35), whereas at three months only 
the proxy respondents (carers/care staff) noted the improvement (a small 
standardised difference of 0.30). Participants in the intervention group also 
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improved in their activities of daily living at three months (a very small 
standardised difference of 0.15). There were no significant differences in other 
outcomes at either three or six months. The sub-study results suggest that 
people on ACHEI medication may benefit cognitively from maintenance CST 
suggesting a synergistic effect. This is in line with other studies combining 
ACHEIs and cognitive stimulation4,8,13,  and the Cochrane review2 which found 
that the effect of cognitive stimulation on cognition is over and above the 
effects of medication alone. The relevance in terms of clinically significant 
change is less clear. A mean decrease of 1 point versus 4 points on the 
MMSE scale may make a big difference for some people with dementia. The 
difference might translate into economic benefits since a difference of 1 point 
in the MMSE score may be associated with substantial reductions in the costs 
of caring for people with dementia27. The CST programme prior to baseline 
resulted in mean improvements of 4.4 points on the ADAS-Cog and 2.7 points 
on the MMSE13. Since dementia is associated with progressive cognitive 
decline there may have been limited potential for further cognitive 
improvement with the maintenance programme. This means that at six-month 
follow-up both groups were likely to have declined from the baseline taken 
after the CST groups finished, and so significant differences in cognition were 
only likely to be found if the usual care (CST only) group had declined more 
than the maintenance group.  
 
Strengths and limitations 
As participants came from nine care homes and nine community services 
across London, Essex and Bedfordshire, this pragmatic trial is likely to be 
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generalisable in many respects. However, since participants were almost all 
white it is hard to say how far CST is useful for other ethnic or cultural groups. 
Nevertheless, we have recently adapted the CST programme for a south 
Asian population and successfully run a local group in Hindi and Gujarati. 
Although we took great care to blind our researchers to allocated treatment, 
we could not blind those care staff and family carers who provided proxy 
ratings for four measures (ADCS-ADL, NPI, QoL-AD and DEMQOL) and this 
means there is a risk of detection bias. Notably these measures provided 
three of the four significant findings. Compared to the original CST study this 
trial had more diversity in dementia severity due to a much higher proportion 
recruited from the community (50% vs 15%). This resulted in the standard 
deviations of the cognitive measures being much higher than in the original 
trial of CST4. A larger trial might find significant differences in cognition after 
weekly Maintenance CST. However, it may be that more frequent groups 
would be more efficacious. This was the first rigorous trial of Maintenance 
CST. The results are encouraging but not conclusive and suggest that further 
trials are needed  and it will be important for other groups to evaluate 
Maintenance CST.28   
 
Future research could look in more depth at the optimum frequency and 
duration of CST groups, for example to continue to provide CST twice a week 
(rather than once weekly) for a six month period. Another option would be to 
repeat the standard 7 week CST programme for example after a 4 month 
break. However, this option could be disruptive to the groups, and would not 
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mirror the standard approach used in drug interventions which are given 
without interruption rather than as a short course.   
 
Clinical implications 
In the previous stage of this study before and after CST (prior to 
randomisation) we found that both cognition and quality of life significantly 
improved, including for those people on ACHEIs.13 However following 
Maintenance CST at six-month follow-up we found no significant differences 
in cognition. There were no differences on the ADAS-Cog although the MMSE 
showed a 0.85 points advantage for the Maintenance CST group. This does 
not suggest that Maintenance CST has substantial effects on cognition over 
and above the original benefits of the initial CST programme.2  MMSE scores 
in mild to moderate dementia generally decrease by 2 to 4 points per year,29. 
Before the initial CST programme13 (2 months before the start of this RCT) the 
mean ADAS-Cog was 35.0 and the mean MMSE score was 15.8. Eight 
months later at six-month follow-up there was no overall cognitive decline with 
the mean ADAS-Cog scores being 35.9 and 35.3 and the mean MMSE scores 
being 16.3 and 15.5 in the treatment and control groups respectively.  From a 
standardised baseline score of 17.8 on the MMSE; in the ACHEI only group, 
MMSE scores fell to 14.6 points in the 6 months of the maintenance CST trial; 
compared with a decrease to 17.3 in the maintenance CST/ACHEI 
(combined) treatment; and a decrease to 16.3 in the maintenance CST only 
group. This suggests that CST may continue to have some degree of 
protective effect on cognition over and above the effects of medication. Other 
studies using usual care control groups have also found that a programme of 
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cognitive stimulation sessions over a longer time period can be effective in 
reducing cognitive decline in dementia.30,31  
In chronic conditions quality of life may be more important for older adults 
than disease-specific outcomes and it is a key outcome that interventions for 
dementia should target. Benefits to cognition alone may not be sufficient to 
justify an extensive programme of intervention unless they are accompanied 
by other benefits such as quality of life32. Two recent systematic reviews 
highlighted that there are few well-designed studies on the effectiveness of 
either pharmacological33 or psychosocial34 interventions on quality of life. Like 
other follow up studies we found that individual changes in quality of life were 
apparent for nearly three-quarters of our sample35,36,37. In contrast to the 
Cochrane review of cognitive stimulation our study found that activities of daily 
living improved at three-month follow-up. However, previous research35 
suggests that there may be a correlation between proxy rated quality of life 
and activities of daily living. It might be that the effects of the intervention on 
proxy rated quality of life was linked with the effects on activities of daily living. 
At six-month follow-up these proxy rated domains showed no difference. 
However, for the person with dementia a temporary improvement in quality of 
life, cognition, or activities of daily living may all be considered worthwhile 
Future research  
As this was the first rigorous trial of Maintenance CST, we encourage others 
to implement and evaluate this novel extension in other populations in other 
contexts with other staff. In our research programme we have three further 
cognitive stimulation therapy studies28 Firstly, we are undertaking a pragmatic 
 20 
cluster randomised implementation trial to compare staff trained in CST 
receiving either (1) additional support (web support, regular phone support) or 
(2) no support. This will evaluate whether additional staff support results in 
more CST group attendances. Secondly, we are conducting an 
implementation in practice study measuring minimal outcomes (cognition and 
quality of life) for centres running CST/Maintenance CST groups.  Lastly, we 
have developed a version of CST for use by the family carer (individual CST) 
and this is currently being evaluated in a large multicentre trial funded by the 
NIHR/HTA38.  
 
In conclusion, standard CST can improve cognition and quality of life39. This 
trial indicates that the weekly Maintenance CST over 24 weeks provides some 
potential benefit beyond the basic CST programme. Further research should 
evaluate whether long-term CST should be provided more frequently than 
once a week. Over the 8 months (from the original baseline before 2 months 
of CST and the 6-month follow-up), the average cognitive decline in both the 
maintenance CST and usual care groups was considerably less than would 
normally be expected in practice suggesting the original CST programme had 
some residual beneficial effect. Maintenance CST may offer short and long 
term benefits to quality of life. The sub study of maintenance CST with 
ACHEIs provides initial evidence that maintenance Cognitive Stimulation 
Therapy in combination with ACHEI medication may have longer term 
benefits to cognition. Pharmacological and psychosocial interventions may 
potentially work better together than either alone.  
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Figure 1. Consort flowchart of participants’ progress 
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Table 1.  Baseline characteristics of 236 participants in maintenance CST trial 
 
Participants at Baseline 0: Before start of CST groups 272 
Total lost from the beginning of CST groups 36 
 
Reason for withdrawal  
Did not like CST groups and wanted to withdraw  17 (49%) 
Health issues 15 (40%) 
Difficulties with group time or other participants  2 (6%) 
 Moved to a different care home   2 (6%) 
Participants at Baseline 1 - After completion of CST groups  236  
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Table 2. Baseline characteristics of 236 participants by allocated group 
 
 Intervention (n=123) Control (n=113)  
Characteristics Number (%) Number (%) 
 
Female 80 (65%)  70 (62% ) 
Ethnicity: white 111 (90%)  104 (92%) 
Marital status (widow) 54 (44%)  57 (50%) 
Dementia diagnosis (AD) 38 (31%)  35 (31%) 
On AChEIs  42 (34%)  34 (30%) 
In Care Home 51 (41%)  50 (44%) 
 
 Mean (SD) Mean (SD) 
Age (years):  82.7 (7.9) 83.5 (7.2) 
ADAS-Cog  31.1 (14.6) 33.2 (13.0) 
QoL-AD  36.1 (4.8) 36.5 (5.7) 
MMSE  17.8 (5.6) 17.8 (5.4) 
DEMQOL  94.8 (10.9) 95.1 (11.7) 
NPI   13.8 (12.9) 11.3 (9.1) 
ADCS-ADL  42.7 (17.2) 41.5 (18.1) 
Proxy QoL-AD  33.7 (5.9) 33.3 (4.9) 
Proxy DEMQOL  102.2 (13.5) 102.2 (11.2) 
 
AChEIs - Acetylcholinesterase Inhibitors  
 
ADAS-Cog - Alzheimer’s Disease Assessment Scale – Cognition Subscale  
QoL-AD - Quality of Life in Alzheimer's Disease scale  
MMSE - Mini-Mental State Examination 
DEMQOL - Dementia Quality of Life scale  
NPI - Neuropsychiatric Inventory  
ADCS-ADL - Alzheimer's Disease Co-operative Study-Activities of Daily Living scale
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Table 3. Effects of Maintenance CST on adjusted imputed outcomes at primary and secondary end points  
 Primary end point - 6 month follow up Secondary end point  3-month follow up  
Adjusted 
outcomes 
Treatment Control Differencea 
Significance 
level Treatment Control Differencea 
Significance 
level 
Mean (SE) Mean (SE) 
Mean  
(95% CI) 
Median of 5 
imputations Mean (SE) Mean (SE) 
Mean  
(95% CI) 
Median of 5 
imputations 
ADAS-Cogb 
 
35.94 (2.79) 
 
35.29 (2.85) 
 
-0.65  
(-3.71 to 2.42) 
.67 
 
35.32 (2.56) 
 
34.47 (2.59) 
 
-0.85  
(-3.40 to 1.70) 
.27 
 
QoL-ADc 
 
35.62 (1.43) 
 
33.84 (1.53) 
 
1.78  
(-0.01 to 3.57) 
.03 
 
34.29 (1.03) 
 
33.97 (1.04) 
 
0.32  
(-0.88 to 1.52) 
.54 
 
MMSEc 
 
16.34 (1.21) 
 
15.49 (1.25) 
 
0.85 
(-0.29 to 1.99) 
.15 
 
16.09 (0.88) 
 
15.79 (0.91) 
 
0.30  
(-0.72 to 1.31) 
.56 
 
DEMQOLc 
 
89.13 (3.55) 
 
88.83 (3.56) 
 
0.30  
(-2.70 to 3.31) 
.87 
 
89.85 (2.34) 
 
90.71 (2.38) 
 
-0.86  
(-3.45 to 1.73) 
.54 
 
NPIb 
 
18.76 (3.78) 
 
20.35 (3.94) 
 
1.58  
(-2.67 to 5.84) 
.53 
 
14.71 (2.84) 
 
16.18 (2.76) 
 
1.47  
(-1.59 to 4.53) 
.34 
 
ADCS-ADLc 
 
43.29 (2.88) 
 
42.35 (2.87) 
 
0.94  
(-2.04 to 3.92) 
.54 
 
43.58 (2.32) 
 
40.94 (2.32) 
 
2.64  
(0.08 to 5.20) 
.04 
 
Proxy QoL-ADc 
 
34.12 (1.41) 
 
34.05 (1.41) 
 
0.07  
(-1.39 to 1.53) 
.95 
 
33.93 (1.05) 
 
32.40 (1.07) 
 
1.53  
(0.37 to 2.69) 
.01 
 
Proxy DEMQOLc 
 
97.75 (3.23) 
 
96.61 (3.21) 
 
1.13  
(-2.24 to 4.51) 
.50 
 
101.36 (2.67) 
 
98.12 (2.67) 
 
3.24  
(0.29 to 6.19) 
.03 
 
a Positive differences favour maintenance CST.  
b Lower scores show better outcome 
c Higher scores show better outcome 
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Table 4. Effects of Maintenance CST on adjusted imputed outcomes at primary and secondary end point according to ACHEI treatment.  The significance levels quoted are  
for the interaction term of treatment group and receipt of ACHEIs. 
   Baseline 3 months  6 months  
 Group n Mean SE 
Model  
adjusted 
mean 
SE Interaction  p 
Model 
adjusted 
mean 
SE Interaction  p 
ADAS-Cog      .13   .71 
 ACHEI  
34 
  
31.29 
(27.17 to 35.41) 
2.09 
 
37.05 
(31.23 to 42.87) 
2.84 
  
36.52 
(29.47 to 43.58) 
 
3.53 
  
 TAU  
79 
 
34.03 
(31.08 to 36.99) 
1.5 
 
32.35 
(26.77 to 37.92) 2.68  
34.67 
(28.81 to 40.52) 2.97  
 ACHEI/MCST  
42 
 
28.65 
(25.14 to 32.16) 
1.78 
 
36.55 
(29.94 to 43.16) 3.16  
35.77 
(29.33 to 42.22) 3.28  
 MCST   
81 
 
32.4 
(28.91 to 35.89) 
1.77 
 
33.85 
(28.47 to 39.22) 2.57  
35.99 
(30.07 to 41.91) 
 
2.98  
QOL-AD       .97   .48 
 ACHEI 34  37.73 (36.24 to 39.22) .76 
32.81 
(30.4 to 35.22) 1.23  
33.94 
(30.23 to 37.65) 1.86  
 TAU 79 35.99 (34.64 to 37.34) .69 
35.13 
(32.98 to 37.27) 1.09  
33.81 
(30.83 to 36.79) 1.52  
 ACHEI/MCST 42 37.08 (35.56 to 38.6) .77 
33.14 
(30.66 to 35.63) 1.27  
34.72 
(31.39 to 38.06) 1.7  
 MCST  81 35.62 (34.58 to 36.67) .53 
35.45 
(33.39 to 37.5) 1.05  
36.07 
(33.25 to 38.89) 1.44  
NPI       .99   .26 
 ACHEI 34  12.13 (8.94 to 15.32) 1.62 
17.23 
(10.77 to 23.69) 3.28  
23.78 
(14.85 to 32.71) 4.54  
 TAU 79 11 (9.01 to 12.99) 1.01 
15.12 
(9.51 to 20.74) 2.86  
17.15 
(9.08 to 25.23) 4.11  
 MCST/ACHEI 42 16.15 (10.77 to 21.53) 2.73 
15.85 
(9.17 to 22.53) 3.39  
18.21 
(9.44 to 26.98) 4.47  
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 MCST  81 12.65 (10.58 to 14.72) 1.05 
13.61 
(8.03 to 19.19) 2.82  
17.49 
(10.05 to 24.93) 3.79  
ADL       .80   .80 
 ACHEI 34  44.03 (38.35 to 49.71) 2.88 
41.51 
(36.04 to 46.98) 2.79  
42.45 
(35.9 to 49) 3.34  
 TAU 79 40.42 (36.28 to 44.56) 2.10 
40.37 
(35.53 to 45.22) 2.47  
42.22 
(36.26 to 48.17) 3.04  
 MCST/ACHEI 42 48.24 (42.59 to 53.89) 2.87 
43.83 
(38.21 to 49.45) 2.87  
43.91 
(37.12 to 50.69) 3.46  
 MCST only 81 39.78 (36.32 to 43.23) 1.75 
43.17 
(38.59 to 47.75) 2.34  
42.91 
(37.18 to 48.64) 2.92  
MMSE      .03   .03 
 ACHEI 34  18.85 (17.29 to 20.41) .79 
15.26 
(13.13 to 17.39) 1.08  
14.62 
(11.81 to 17.43) 1.40  
 TAU 79 17.33 (16.08 to 18.58) .63 
16.25 
(14.44 to 18.05) .92  
16.26 
(13.68 to 18.84) 1.28  
 MCST/ACHEI 42 18.27 (16.62 to 19.91) .84 
17.17 
(15.09 to 19.25) 1.06  
17.25 
(14.63 to 19.87) 1.33  
 MCST  81 17.55 (16.29 to 18.8) .64 
15.77 
(14.03 to 17.5) .88  
16.26 
(13.71 to 18.8) 1.26  
DEMQOL      .92   .97 
 ACHEI 34  
97.90 
(94.93 to 
100.87) 
1.51 89.13 (83.62 to 94.65) 2.81  
87.93 
(80 to 95.87) 3.90  
 TAU 79 93.86 (91.07 to 96.66) 1.42 
92.25 
(87.33 to 97.17) 2.51  
89.75 
(82.03 to 97.46) 3.74  
 ACHEI/MCST 42 
97.36 
(94.35 to 
100.36) 
1.53 88.99 (83.33 to 94.66) 2.89  
87.88 
(80.13 to 95.62) 3.86  
 MCST  81 93.49 (91.02 to 95.97) 1.26 
91.04 
(86.4 to 95.68) 2.37  
90.22 
(82.54 to 97.9) 3.69  
 
